Study on Female Patients' Mammographic Texture Features

NCT ID: NCT06469606

Last Updated: 2024-06-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-17

Study Completion Date

2038-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mammography is the most common method for breast imaging, and it provides information for model building and analysis. Radiomics applied to mammography has the potential to revolutionize clinical decision-making by providing valuable insights into risk assessment and disease detection. Despite this, the influence of imaging parameters and clinical and biological factors on radiological texture features remains poorly understood. There is a pressing need to overcome the obstacle of system-inherent effects on mammographic images to facilitate the translation of radiological texture features into routine clinical practice by enabling reliable and robust AI-based or AI-aided decision-making. Furthermore, understanding the relationship between imaging parameters, textural features, and clinical and biological information supports the clinical use of AI. The objective of this study is to evaluate AI methods for clinical practice and to study how it relates to clinical factors and biological features.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Artificial Intelligence Mammography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participant diagnosed with breast cancer

Participants diagnosed with breast cancer who will undergo a mastectomy operation

Group Type EXPERIMENTAL

AI tool

Intervention Type DEVICE

Both the arms will undergo the use of "AI tool" developed in the group. The tool will be trained to detect outcomes.

Participant not diagnosed with breast cancer

Participants who will undergo a mastectomy operation for a non-breast cancer related clinical indication

Group Type EXPERIMENTAL

AI tool

Intervention Type DEVICE

Both the arms will undergo the use of "AI tool" developed in the group. The tool will be trained to detect outcomes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AI tool

Both the arms will undergo the use of "AI tool" developed in the group. The tool will be trained to detect outcomes.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Candidate is a biological female aged 18 years or above;
* Candidate is willing and able to give informed consent and gives their written consent for the participation in the study;
* There is a clinical indication for a uni- or bilateral mastectomy

Exclusion Criteria

* Candidate lacks the capacity to provide informed consent;
* Candidate has breast implants
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tampere University

OTHER

Sponsor Role collaborator

Kuopio University Hospital

OTHER

Sponsor Role collaborator

University of Eastern Finland

OTHER

Sponsor Role collaborator

University of Turku

OTHER

Sponsor Role collaborator

University of Oulu

OTHER

Sponsor Role collaborator

Tampere University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Otso Arponen, MD, PhD

Role: CONTACT

+3583311611

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R23077

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.